Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation
- PMID: 33466428
- PMCID: PMC7824823
- DOI: 10.3390/pharmaceutics13010059
Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation
Abstract
Gemcitabine (Gem) and cisplatin (Cis) are currently being used for lung cancer treatment, but they are highly toxic in high dosages. This research aimed to develop a niosome formulation containing a low-dosage Gem and Cis (NGC), as an alternative formulation for lung cancer treatment. NGC was prepared using a very simple heating method and was further optimized by D-optimal mixture design. The optimum NGC formulation with particle size, polydispersity index (PDI), and zeta potential of 166.45 nm, 0.16, and -15.28 mV, respectively, was obtained and remained stable at 27 °C with no phase separation for up to 90 days. The aerosol output was 96.22%, which indicates its suitability as aerosolized formulation. An in vitro drug release study using the dialysis bag diffusion technique showed controlled release for both drugs up to 24 h penetration. A cytotoxicity study against normal lung (MRC5) and lung cancer (A549) cell lines was investigated. The results showed that the optimized NGC had reduced cytotoxicity effects against both MRC5 and A549 when compared with the control (Gem + Cis alone) from very toxic (IC50 < 1.56 µg/mL) to weakly toxic (IC50 280.00 µg/mL) and moderately toxic (IC50 = 46.00 µg/mL), respectively, after 72 h of treatment. These findings revealed that the optimized NGC has excellent potential and is a promising prospect in aerosolized delivery systems to treat lung cancer that warrants further investigation.
Keywords: aerosol output; cisplatin; gemcitabine; heating method; lung cancer; niosome.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Optimization of nanoemulsion containing gemcitabine and evaluation of its cytotoxicity towards human fetal lung fibroblast (MRC5) and human lung carcinoma (A549) cells.Int J Nanomedicine. 2019 Sep 9;14:7323-7338. doi: 10.2147/IJN.S212635. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31686809 Free PMC article.
-
Optimization of Quercetin loaded Palm Oil Ester Based Nanoemulsion Formulation for Pulmonary Delivery.J Oleo Sci. 2018 Aug 1;67(8):933-940. doi: 10.5650/jos.ess17253. Epub 2018 Jul 17. J Oleo Sci. 2018. PMID: 30012897
-
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.J Pharm Pharmacol. 2006 Mar;58(3):327-36. doi: 10.1211/jpp.58.3.0006. J Pharm Pharmacol. 2006. PMID: 16536899
-
Formulation Design, Statistical Optimization, and In Vitro Evaluation of a Naringenin Nanoemulsion to Enhance Apoptotic Activity in A549 Lung Cancer Cells.Pharmaceuticals (Basel). 2020 Jul 15;13(7):152. doi: 10.3390/ph13070152. Pharmaceuticals (Basel). 2020. PMID: 32679917 Free PMC article.
-
In vitro evaluation of the inhalable quercetin loaded nanoemulsion for pulmonary delivery.Drug Deliv Transl Res. 2019 Apr;9(2):497-507. doi: 10.1007/s13346-018-0509-5. Drug Deliv Transl Res. 2019. PMID: 29541999
Cited by
-
Inhaled Medicines for Targeting Non-Small Cell Lung Cancer.Pharmaceutics. 2023 Dec 14;15(12):2777. doi: 10.3390/pharmaceutics15122777. Pharmaceutics. 2023. PMID: 38140117 Free PMC article. Review.
-
Current advances in niosomes applications for drug delivery and cancer treatment.Mater Today Bio. 2023 Oct 21;23:100837. doi: 10.1016/j.mtbio.2023.100837. eCollection 2023 Dec. Mater Today Bio. 2023. PMID: 37953758 Free PMC article. Review.
-
Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells.Front Oncol. 2023 Aug 17;13:1193708. doi: 10.3389/fonc.2023.1193708. eCollection 2023. Front Oncol. 2023. PMID: 37664043 Free PMC article.
-
Size-Controlled Preparation of Docetaxel- and Curcumin-Loaded Nanoemulsions for Potential Pulmonary Delivery.Pharmaceutics. 2023 Feb 15;15(2):652. doi: 10.3390/pharmaceutics15020652. Pharmaceutics. 2023. PMID: 36839974 Free PMC article.
-
Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.Pharmaceutics. 2022 Dec 31;15(1):139. doi: 10.3390/pharmaceutics15010139. Pharmaceutics. 2022. PMID: 36678768 Free PMC article. Review.
References
-
- An Q., Shi C.X., Guo H., Xie S.M., Yang Y.Y., Liu Y.N., Liu Z.H., Zhou C.Z., Niu F.J. Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small cell lung cancer. Pharm. Dev. Technol. 2019;24:1164–1174. doi: 10.1080/10837450.2019.1647236. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
